Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 29 March 2024, 14:19 HKT/SGT
Share:
    

Source: Eisai
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that “NouKNOW®”, Eisai’s self-check tool for brain health, was certified as a “ME-BYO BRAND” by Kanagawa prefecture.

About ”ME-BYO BRAND”

“ME-BYO BRAND”, is a certification granted to excellent products/services associated with pre-symptomatic diseases by Kanagawa Prefectural Government in an effort to raise awareness toward pre-symptomatic diseases and promote commercialization of endorsed products/services. It recognizes products/services that contribute to the visualization of pre-symptomatic diseases in the areas of lifestyle, life functions, mental health/stress, and cognitive function, which lead to changes in the awareness and behavior of Kanagawa prefecture residents.

“NouKNOW”, a Self-Check Tool for Brain Health

NouKNOW (non-medical device) is a tool that uses a simple card test using a PC, tablet or smartphone device to perform tests evaluating psychomotor function, attention, learning and memory, and working memory. The results screen displays quantified indicators of brain performance, such as “memorization”, “cognition”, and “decision”, along with lifestyle advice. This digital tool allows users to self-assess independently and in a short time frame (approx. 15 minutes), enabling regular assessments in instances such as daily life and health checkups. It has been adopted by a number of medical and research institutions, municipalities, corporations and universities. It is expected that use of this tool to perform regular self-checks of brain health will become an opportunity to help the generation currently in their prime working years to gain a correct understanding of brain health and diseases, as well as to reconsider daily lifestyle, greater preventive measures, and consultation with doctors and other healthcare professionals.

For additional information, please visit https://nouknow.jp/. (Japanese only)
(List of partners: https://nouknow.jp/partner/

*The purpose of this tool is not to prevent or diagnose disease, but to raise awareness of brain health through regular checks.

Eisai will collaborate with local governments across Japan to create a community where citizens are aware of and check their brain health from the stage where they are healthy, aiming to realize a “Dementia-Inclusive Society” where everyone can live their lives how they would like.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 25, 2024 09:30 HKT/SGT
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
July 23, 2024 19:23 HKT/SGT
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
July 12, 2024 11:56 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 11, 2024 09:00 HKT/SGT
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong
July 2, 2024 12:01 HKT/SGT
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
June 28, 2024 14:57 HKT/SGT
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
June 21, 2024 14:35 HKT/SGT
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City
June 10, 2024 17:50 HKT/SGT
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
June 3, 2024 16:08 HKT/SGT
Eisai Named to List of The Time 100 Most Influential Companies
June 3, 2024 14:22 HKT/SGT
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: